Introduction
Benign Prostatic Hyperplasia (BPH) and chronic prostatitis represent significant clinical challenges in urology, particularly among aging men. While the etiology of these conditions is multifactorial, the disruption of the hormonal milieu—specifically the balance between estrogen and androgen—is widely considered a primary driver of prostatic inflammation. Current research suggests that BPH may be an immune-mediated inflammatory disease. However, the specific dose-response relationship between these hormones and the resulting inflammatory microenvironment remains insufficiently characterized. This study utilizes a castrated Sprague-Dawley (SD) rat model to investigate how varying concentrations of dihydrotestosterone (DHT) and estradiol (E) influence histological inflammation and the expression of key cytokines.
Methodology
The study utilized 53 male SD rats (aged 3–4 months), categorized into a sham-operated blank group, a castration-only group, and multiple hormone-treatment groups. Castration was performed via bilateral orchiectomy to eliminate endogenous hormone production. Following a one-month recovery and treatment period involving daily subcutaneous injections of DHT and E at varying concentrations, prostate specimens were harvested.
Histological analysis was conducted using Hematoxylin-eosin (HE) staining to evaluate the anatomical location, extent, and density of inflammatory cell infiltration, adhering to the International Prostatitis Diagnosis and Grading Standard. Additionally, immunohistochemical (IHC) staining was employed to quantify the expression of Transforming Growth Factor-beta 1 (TGF-β1), Interleukin-6 (IL-6), and Interleukin-8 (IL-8), which serve as markers for tissue stress and inflammatory signaling.
Results
The Non-Linear Response to Androgen
A pivotal finding of this research is the non-linear relationship between androgen concentration and prostatic inflammation. When the concentration of exogenous estrogen was held constant (0.05 mg/kg), increasing DHT levels from 0 to 0.15 mg/kg resulted in a progressive increase in inflammatory cell infiltration and anatomical involvement scores.
However, the study identified a distinct "inflection point" at a DHT concentration of 0.5 mg/kg. When DHT levels were increased further to 1.5 mg/kg, the inflammation scores did not continue to rise; instead, they plateaued or even decreased. This suggests that while androgens can promote inflammation at certain levels, supra-physiological doses may trigger inhibitory pathways that mitigate the inflammatory response.
Estrogen as an Inflammatory Potentiator
In contrast to the complex response seen with DHT, the effect of estrogen was more linear. When DHT concentrations were held constant, increasing the dosage of exogenous estradiol led to a steady increase in both the anatomical extent and the density of inflammatory infiltration. This reinforces the hypothesis that estrogen acts as a primary potentiator of the inflammatory environment within the prostate, particularly as androgen levels naturally decline with age.
Molecular Biomarkers of Inflammation
The expression of TGF-β1, IL-6, and IL-8 closely mirrored the histological findings. The positive rate of TGF-β1 was significantly higher in the hormone-treated groups compared to the blank group ($P < 0.05$). Similar to the histological scores, the expression of TGF-β1 and IL-8 increased as DHT rose toward 0.5 mg/kg but showed a relative decrease in the 1.5 mg/kg DHT group. These findings validate these cytokines as reliable indicators of the severity of hormone-induced prostatic inflammation.
Discussion and Conclusion
This study provides a nuanced understanding of the hormonal regulation of the prostate. The identification of an "inflection point" in the estrogen-to-androgen ratio suggests that therapeutic strategies for BPH and prostatitis should focus on achieving an optimal hormonal balance rather than simply suppressing or supplementing individual hormones.
While the results are compelling, the authors note limitations including the relatively small sample size per subgroup and the short duration of the study (one month) compared to the chronic nature of human prostatic disease. Future research should focus on the molecular mechanisms underlying the observed inflection point, potentially exploring how high androgen levels might suppress specific pro-inflammatory signaling pathways in prostatic stromal cells. Ultimately, these findings pave the way for more targeted, ratio-based hormonal therapies in clinical urology.
Summary updated